Dr Reddy’s stepping up focus on Indian market

M. V. Ramana, CEO, Branded Markets (India & Emerging Markets), Dr Reddy’s

Dr Reddy’s Laboratories is stepping up its focus on the domestic market with a multi-pronged strategy.

The Hyderabad-based drug maker began to focus on bringing innovative drugs to the Indian market a few years ago and it helped it expand its ready reach steadily and to register double digit growth, according to  M. V. Ramana, CEO, Branded Markets (India & Emerging Markets), Dr Reddy’s.

In FY25, Dr Reddy’s earned a revenue of ₹53.7 billion registering a yoy growth of 16 per cent. “The growth was driven by revenues from the vaccine-portfolio in-licensed from Sanofi India, successful new product launches and price increase,’‘ Ramana said. The total number of products launched in FY25 was 23.

As per IQVIA, Dr Reddy’s rank in the Indian pharma market is 10. To be among the top five players in the Indian market, Dr Reddy’s is adopting a multi-pronged strategy of bringing more innovative products along with catering to the needs of consumer health and digital health products, Ramana said. 

Dr Reddy’s has a collaboration with global major Nestle Health Sciences and has already launched some products and plans to bring more popular brands of Nestle to India in the coming days. 

The company is also focussing on the emerging market segment of digital therapeutics. Last year it launched a device for neuro modulation which helps patients with migraine and more digital therapeutic devices are in the pipeline. 

“India is a very important market for us and we continue to step up our focus on the domestic market,’‘ Ramana said.

Published on May 13, 2025